Nuevocor Doses First Patient in SUNBEAM-LMNA Phase 1/2 Trial and Receives FDA Fast Track Designation for NVC-001 in LMNA Dilated Cardiomyopathy
NVC-001 is designed to target the mechanobiological root cause of LMNA dilated cardiomyopathy and has disease-modifying potential SINGAPORE, PARIS and PHILADELPHIA, Oct. 8, 2026 /PRNewswire/ -- Nuevocor, a clinical-stage biotechnology company...
Nuevocor Appoints Dr. Monica Shah as Chief Medical Officer
SINGAPORE, PARIS and PHILADELPHIA, April 28, 2026 /PRNewswire/ -- Nuevocor, a clinical-stage biotechnology company developing novel therapies for patients suffering from life-threatening cardiomyopathies, today announced the appointment of Monica...
Nuevocor Announces FDA Clearance of IND for NVC-001 for LMNA-Related Dilated Cardiomyopathy
LMNA-related dilated cardiomyopathy (LMNA DCM) is one of the most aggressive forms of DCM, affecting approximately 100,000 individuals in the United States and Europe, who progress rapidly to end-stage heart failure. NVC-001 demonstrated significant...
Nuevocor Closes US$45 Million Series B Financing for Clinical Development of Novel Mechanobiology-Centered Therapy for Cardiomyopathy
– Round co-led by new investors, Kurma Partners and Angelini Ventures, with significant participation from existing investors EDBI, ClavystBio, and Boehringer Ingelheim Venture Fund – Proceeds will support the Phase 1/2 clinical trial of lead...